Overexpression of Class III β-tubulin, Sox2, and nuclear Survivin is predictive of taxane resistance in patients with stage III ovarian epithelial cancer.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Source:
      Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE
    • Publication Information:
      Original Publication: London : BioMed Central, [2001-
    • Subject Terms:
    • Abstract:
      Background: Class III β-tubulin, Sox2, and Survivin play important roles in tumor survival and proliferation. However, the association of these three factors with clinicopathological characteristics, chemoresistance, and survival in patients with ovarian cancer remains controversial.
      Methods: We investigated the predictive value and correlation among the expression levels of Class III β-tubulin, Sox2, and Survivin in 110 patients with stage III ovarian epithelial cancer, including 58 patients who received taxane-based chemotherapy and 52 patients who received non-taxane-based chemotherapy. Expression of these three factors was immunohistochemically examined in 110 ovarian tumor tissues obtained from patients before chemotherapy.
      Results: The positive expression rates for Class III β-tubulin, Sox2, and Survivin in ovarian tumor tissues were 59.09 %, 61.82 % and 52.73 %, respectively. The expression of nuclear Survivin and Class III β-tubulin was consistent with that of Sox2 (p = 0.005 and 0.020, respectively). Positive expression of Class III β-tubulin, Sox2, and nuclear Survivin was significantly associated with chemoresistance to taxane-based chemotherapy (p = 0.006, 0.007, and 0.009, respectively), but not to non-taxane-based chemotherapy. Additionally, overexpression of Class III β-tubulin, Sox2, and nuclear Survivin predicted poor progression-free survival in patients receiving taxane-based chemotherapy (p = 0.032, 0.005, and 0.004, respectively).
      Conclusions: These findings suggest that overexpression of Class III β-tubulin, Sox2, and nuclear Survivin might be predictive of taxane resistance and poor progression-free survival in patients with stage III ovarian epithelial cancer. Expression of these three factors may show positive correlations in these patients.
    • References:
      Cancer Lett. 2013 Oct 10;339(2):237-46. (PMID: 23791886)
      Clin Cancer Res. 2011 Jun 1;17(11):3716-26. (PMID: 21512144)
      Clin Exp Metastasis. 2014 Jan;31(1):101-10. (PMID: 24005572)
      J Clin Invest. 1997 Sep 1;100(5):1282-93. (PMID: 9276747)
      J Cell Physiol. 2003 Oct;197(1):8-29. (PMID: 12942537)
      Mod Pathol. 2004 Feb;17(2):264. (PMID: 14963460)
      Clin Cancer Res. 2012 May 15;18(10):2964-75. (PMID: 22438565)
      Cancer. 2007 Jan 15;109(2):228-38. (PMID: 17167759)
      Gynecol Oncol. 2011 Sep;122(3):573-9. (PMID: 21665249)
      J Exp Clin Cancer Res. 2009;28:29. (PMID: 19245702)
      Cell. 2012 Feb 3;148(3):399-408. (PMID: 22304911)
      Biochem J. 2013 Mar 15;450(3):459-68. (PMID: 23301561)
      Clin Cancer Res. 2009 Feb 15;15(4):1473-80. (PMID: 19228748)
      Cancer Res. 2010 Oct 15;70(20):7992-8002. (PMID: 20807808)
      Semin Cancer Biol. 2004 Aug;14(4):231-43. (PMID: 15219616)
      Cell Prolif. 2012 Jun;45(3):207-16. (PMID: 22469032)
      Cancer Res. 2004 Dec 1;64(23):8708-14. (PMID: 15574781)
      Mol Cancer Ther. 2005 Dec;4(12):2001-7. (PMID: 16373715)
      J Cancer Res Clin Oncol. 2011 Jan;137(1):131-7. (PMID: 20349085)
      Br J Cancer. 2005 Jan 31;92(2):271-7. (PMID: 15655541)
      Int J Oncol. 2006 Feb;28(2):375-81. (PMID: 16391792)
      Genes Dev. 1999 Feb 1;13(3):239-52. (PMID: 9990849)
      Gene. 2008 Feb 15;409(1-2):100-8. (PMID: 18178340)
      J Biol Chem. 2001 Dec 14;276(50):47296-302. (PMID: 11584012)
      Mod Pathol. 2003 Jun;16(6):574-83. (PMID: 12808063)
      Cell Mol Life Sci. 2002 Aug;59(8):1406-12. (PMID: 12363043)
      Oncologist. 2013;18(7):787-94. (PMID: 23853246)
      Clin Cancer Res. 2006 May 1;12(9):2774-9. (PMID: 16675570)
      J Ovarian Res. 2011 Nov 10;4(1):20. (PMID: 22075440)
      Cancer Res. 2013 Sep 1;73(17):5544-55. (PMID: 23867475)
      Clin Cancer Res. 2005 Aug 1;11(15):5481-6. (PMID: 16061864)
      Int J Gynecol Pathol. 2013 Jul;32(4):358-67. (PMID: 23722508)
      Int J Gynecol Cancer. 2013 Feb;23(2):256-63. (PMID: 23358177)
      Carcinogenesis. 2014 Mar;35(3):613-23. (PMID: 24233838)
      Cancer Res. 2011 Jul 1;71(13):4640-52. (PMID: 21712410)
      Int J Oncol. 2001 Sep;19(3):537-42. (PMID: 11494033)
      Clin Cancer Res. 2005 Jan 1;11(1):298-305. (PMID: 15671559)
      Oncol Rep. 2011 Nov;26(5):1069-74. (PMID: 21811761)
      CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90. (PMID: 21296855)
      J Clin Oncol. 2007 Sep 20;25(27):4168-70. (PMID: 17724348)
      Hum Pathol. 2012 Sep;43(9):1405-12. (PMID: 22401770)
      Ann Surg Oncol. 2009 Dec;16(12):3488-98. (PMID: 19657699)
      Int J Cancer. 2005 Apr 20;114(4):509-12. (PMID: 15578717)
      Nat Med. 1997 Aug;3(8):917-21. (PMID: 9256286)
      Am J Obstet Gynecol. 2013 Jul;209(1):62.e1-9. (PMID: 23583215)
    • Accession Number:
      0 (Antineoplastic Agents)
      0 (BIRC5 protein, human)
      0 (Inhibitor of Apoptosis Proteins)
      0 (SOX2 protein, human)
      0 (SOXB1 Transcription Factors)
      0 (Survivin)
      0 (TUBB3 protein, human)
      0 (Taxoids)
      0 (Tubulin)
    • Publication Date:
      Date Created: 20150723 Date Completed: 20160510 Latest Revision: 20220317
    • Publication Date:
      20240829
    • Accession Number:
      PMC4511538
    • Accession Number:
      10.1186/s12885-015-1553-x
    • Accession Number:
      26198101